Acta Oncologica最新文献

{"title":"Preliminary feasibility of pre-treatment F-18-PSMA-1007 PET/CT in dose prediction for Lu-177-PSMA-I&T therapy.","authors":"Suvi Kokkonen, Vappu Reijonen, Eero Hippeläinen, Veera Ahtiainen, Jukka Schildt, Outi Sipilä, Sauli Savolainen, Mikko Tenhunen","doi":"10.2340/1651-226X.2026.45700","DOIUrl":"10.2340/1651-226X.2026.45700","url":null,"abstract":"","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"609-613"},"PeriodicalIF":2.7,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13402945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148547464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of progressive resistance training on lean soft tissue mass in head and neck cancer patients during concomitant chemoradiotherapy: the DAHANCA 31 randomized controlled trial.","authors":"Camilla K Lonkvist, Simon Lønbro, Anders Vinther, Bo Zerahn, Eva Rosenbom, Mads Vandsted Svart, Morten Lyng Høgild, Hanne Primdahl, Julie Gehl","doi":"10.2340/1651-226X.2026.45545","DOIUrl":"10.2340/1651-226X.2026.45545","url":null,"abstract":"<p><strong>Background and purpose: </strong>Head and neck cancer patients undergoing concurrent chemoradiation treatment (CCRT) lose a significant amount of lean soft tissue mass (LSTM) reducing muscle strength and performance. Progressive resistance training (PRT) may mitigate this loss and improve muscle strength and performance. The purpose was to investigate the effects of PRT initiated at CCRT onset on LSTM, muscle strength, and functional performance compared with usual care.</p><p><strong>Patients/material and methods: </strong>Patients were randomized to 12 weeks of PRT (36 sessions) or usual care with no exercise (control group [CON]). At baseline, after 6 and 12 weeks, 6 and 12 months, Dual-Energy Absorptiometry evaluated total body mass (BM), LSTM, and fat mass (FM); 1 repetition maximum (1RM) chest press and leg press test assessed maximal muscle strength and functional performance (30 seconds chair-rise; 30 seconds arm curls; stair climb) was evaluated. Dietary intake was registered as were Quality of Life questionnaires European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) C30 and QLQ H&N-35. A sample size of 72 patients (36 per group) was determined a priori with LSTM as the primary endpoint.</p><p><strong>Results: </strong>Fifty patients were included (required sample size was not met), 25 in each group. From baseline to 12 weeks, patients in the PRT group lost 8.6 ± 1.0 kg BM (10%), 3.4 ± 0.6 kg LSTM (6%), and 5.2 ± 0.8 kg FM (21%). This was not significantly different from the CON group losing 7.4 ± 1.0 kg BM (9%), 3.4 ± 0.6 kg LSTM (6%), and 4.0 ± 0.8 FM (17%). Likewise, 1RM decreased equally in both groups. Chair rise and arm curl performance improved significantly more in PRT compared with in CON (p < 0.05).</p><p><strong>Interpretation: </strong>In this study PRT initiated at CCRT onset did not attenuate loss of LSTM or muscle strength. However, PRT did result in significantly increased functional performance.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"599-608"},"PeriodicalIF":2.7,"publicationDate":"2026-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13358791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148417630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiotoxicity, survival, and dexrazoxane use in patients with soft tissue sarcoma: a Danish population‑based cohort study.","authors":"Joanna Vitfell-Rasmussen, Ninna Aggerholm-Pedersen, Christina Brun Knudsen, Kasper Madsen, Lars Fiksen, Niels Junker, Michael Mørk Petersen, Thomas Kümler, Anders Krarup-Hansen, Bodil Elisabeth Engelmann","doi":"10.2340/1651-226X.2026.45897","DOIUrl":"10.2340/1651-226X.2026.45897","url":null,"abstract":"<p><strong>Background and purpose: </strong>Anthracycline-associated cardiotoxicity is a challenge that dexrazoxane may reduce. The aim of this study was to report the overall survival (OS), incidence of cardiotoxicity and dexrazoxane use in a Danish population-based cohort of patients with soft tissue sarcoma (STS) treated with doxorubicin, olaratumab and dexrazoxane.</p><p><strong>Patients/material and methods: </strong>We performed a retrospective study of adults (≥18 years) with locally advanced or metastatic STS treated with doxorubicin, olaratumab and dexrazoxane between 2015 and 2019 at Herlev University Hospital (Herlev) and Aarhus University Hospital (Aarhus). Dexrazoxane was administered from cycle 1 at Herlev and from cycle 4 at Aarhus. OS was measured from doxorubicin initiation to death. Cardiotoxicity was defined as a >10 percentage‑point decline in left ventricular ejection fraction to <50% compared with baseline.</p><p><strong>Results: </strong>In total, 106 patients were included: 71 patients (67%) from Herlev and 35 (33%) from Aarhus. Mean age was 59 years, 59% were female. Median OS was 18 months (95% confidence interval [CI]: 11.0-20.7) and median cumulative doxorubicin dose was 320.7 mg/m² (range: 37.5-605.4). Dexrazoxane was administered to 68 patients (96%) at Herlev and 18 (51%) at Aarhus. Seven patients (7%) developed cardiotoxicity (Herlev n = 4; Aarhus n = 3). Median OS was 19.6 months at Herlev and 14.8 months at Aarhus (p = 0.24). Neutropenic fever occurred in 27 patients (38%) at Herlev and six patients (17%) at Aarhus (p = 0.88).</p><p><strong>Interpretation: </strong>Doxorubicin with olaratumab and dexrazoxane resulted in a low incidence of cardiotoxicity and OS was consistent with previously reported.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"590-598"},"PeriodicalIF":2.7,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13352963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148395559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overall survival following palliative immune checkpoint inhibitor treatment according to ECOG performance status: a large registry-based study.","authors":"Per Nodbrant, Eva Ulff, Magnus Lagerlund, Sander Ellegård, Olle Eriksson, Freddi Lewin, Kristina Engvall","doi":"10.2340/1651-226X.2026.45827","DOIUrl":"10.2340/1651-226X.2026.45827","url":null,"abstract":"<p><strong>Background and purpose: </strong>Palliative immune checkpoint inhibitor (pICI) treatment has improved overall survival (OS) in many solid tumours during the last decades. However, the survival benefits are based on fit patients included in the clinical trials, all with Eastern Cooperative Oncology Group Performance status (ECOG PS) 0-1. Data on survival in PS 2-3 patients are limited. This study aimed to compare OS according to ECOG PS at the initiation of pICI in real world data. Patient/material and methods: ICI has been recorded in the Swedish National Cancer Drug Registries since 2010. Palliative ICI treatment in the Southeastern region, Sweden, from 2010 until April 2025 were included. Survival probability and median overall survival (mOS) were calculated.</p><p><strong>Results: </strong>A total of 1956 patients had received at least one pICI treatment, for lung cancer (n = 854), melanoma (n = 443), renal carcinoma (n = 218) and urothelial carcinoma (n = 127). PS 2 or higher was reported in 28.9% and 80.6% received ICI only (no chemotherapy). mOS was in PS 0-1 patients 23.4 months, in PS 2 patients 9.6 months and in PS 3 patients 3.8 months. Death within 90 days occurred in 45.7% of PS 3 patients.</p><p><strong>Interpretation: </strong>Less fit patients are commonly treated with pICI, and PS seems an important predictive factor for palliative ICI regardless of cancer subtype. In our data, mOS is particularly short in PS 3 patients, suggesting to refrain from treatment. mOS is shorter in PS 2 patients than in PS 0-1, warranting individual considerations in treatment decisions. Better tools to guide treatment decisions for PS 2 patients are desirable.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"582-589"},"PeriodicalIF":2.7,"publicationDate":"2026-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13343466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148373747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent survival trends in the most fatal cancers in the Nordic countries: gains in some but not in all.","authors":"Kari Hemminki, Frantisek Zitricky, Asta Försti, Akseli Hemminki","doi":"10.2340/1651-226X.2026.45868","DOIUrl":"10.2340/1651-226X.2026.45868","url":null,"abstract":"","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"578-581"},"PeriodicalIF":2.7,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13324887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148343528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathological characteristics and prognosis of very young patients with early breast cancer: a comparative analysis with older patients.","authors":"Youri Park, Jin Hoon Nam, Yeonjoo Kwon, Jung Ho Park, Sanghwa Kim, Young Ah Lim, Hee-Joon Kang, Doyil Kim, Janghee Lee","doi":"10.2340/1651-226X.2026.45584","DOIUrl":"10.2340/1651-226X.2026.45584","url":null,"abstract":"<p><strong>Background and purpose: </strong>It has generally been established that younger breast cancer patients exhibit unfavorable biology and poorer prognosis. However, previous studies have not consistently demonstrated differences between younger and older patients. The objective of this study, therefore, was to compare pathological characteristics and prognosis in young patients (age ≤ 40 years) with early breast cancer with those of older patients (age ≥ 55 years).</p><p><strong>Patients/material and methods: </strong>Individuals diagnosed with early breast cancer (age ≤ 40 years) and those ≥ 55 years of age, who were treated at two hospitals between June 2003 and December 2019, were identified. Oncological outcomes, including recurrence-free survival (RFS), distant RFS (DRFS), and locoregional RFS (LRRFS), were compared between two groups. Kaplan-Meier survival curves and the Cox proportional hazards model were used to evaluate.</p><p><strong>Results: </strong>Data from 288 young (≤ 40 years) and 830 older (≥ 55 years) patients were included. Pathologically, younger patients exhibited a higher prevalence of high-grade tumors. There was no significant difference in RFS and DRFS between the younger and older patient groups (RFS: hazard ratio 1.11 [95% confidence intervals (CI) 0.74-1.66]; P = 0.613; DRFS: hazard ratio 1.03 [95% CI 0.65-1.62]; P = 0.897). However, LRRFS was unfavorable in younger patients (hazard ratio, 2.15; 95% CI, 1.03-4.49; P = 0.043). Subgroup analysis revealed a significant difference in LRRFS among hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients (hazard ratio 4.04 [95% CI 1.17-13.97]; P = 0.027); however, no significant difference was observed in other subtypes.</p><p><strong>Interpretation: </strong>Younger patients with breast cancer exhibited a higher frequency of high-grade tumors, although no differences were observed in RFS and DRFS. However, locoregional recurrence was more common among younger patients, especially HR-positive/HER2-negative breast cancer.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"570-577"},"PeriodicalIF":2.7,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13324888/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148350210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-in-human quantitative [¹⁵O]H₂O PET imaging of tumour blood flow at rest and during exercise in lymphoma patients.","authors":"Milla Perros, Tiia Koivula, Salla Lempiäinen, Tuula Tolvanen, Anna Kirjavainen, Laura Nummijärvi, Carl-Johan Sundberg, Helene Rundqvist, Heikki Minn, Kari Kalliokoski, Ilkka H A Heinonen","doi":"10.2340/1651-226X.2026.45780","DOIUrl":"10.2340/1651-226X.2026.45780","url":null,"abstract":"<p><strong>Background and purpose: </strong>Although exercise is recommended for cancer patients, its acute effects on tumour blood flow (TBF) have not been quantified in humans. As TBF may influence tumour progression and treatment efficacy, we assessed its circulatory responses in malignant lymphoma during exercise using dynamic PET imaging. Patient/material and methods: Eight patients with Hodgkin or non-Hodgkin lymphoma underwent thoracic [¹⁵O]H₂O positron emission tomography/computed tomography (PET/CT) at rest and during 10 min of supine cycling (Borg RPE 11-16). TBF and its heterogeneity, tumour blood volume (TBV), mean transit time (MTT), and vascular resistance were quantified in eight index and three secondary tumours.</p><p><strong>Results: </strong>Baseline TBF in index tumours was high (mean 57.6 mL/dL/min; range 30.3-105.0). During exercise, TBF (mean 48.1 ± 16.1 mL/dL/min), its heterogeneity and MTT did not change significantly. However, TBV decreased (p = 0.038), and vascular resistance tended to increase (p = 0.055). TBF change correlated positively with age (r = 0.73, p = 0.04) and negatively with tumour volume (r = -0.67, p = 0.02), but not with heart rate or power output. Secondary tumours showed similar exercise responses, with lower absolute TBF (p = 0.02).</p><p><strong>Interpretation: </strong>This study demonstrates the feasibility of using [¹⁵O]H₂O PET/CT to quantify TBF in lymphoma patients in real time during acute exercise. Baseline TBF is remarkably high in lymphoma tumours, and responses to acute exercise are variable, tending to decline in younger patients and larger tumours, while vascular resistance tended to increase.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"561-569"},"PeriodicalIF":2.7,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13309985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148306645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Starshot field configuration in the linac isocentre size determination: a comparison of film and electronic portal imaging device measurements.","authors":"Ari-Pekka Honkanen, Antti Kulmala","doi":"10.2340/1651-226X.2026.45692","DOIUrl":"10.2340/1651-226X.2026.45692","url":null,"abstract":"","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"557-560"},"PeriodicalIF":2.7,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13309924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148306641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of 3D-CRT vs. VMAT for radiotherapy of whole breast with simultaneous integrated boost.","authors":"Gracinda Johansson, Rafat Kojoj, Sewa Surdashi, Martin Olin, Emil Fredén, Pelin Sen, Eija Dahl, Camilla Wendt","doi":"10.2340/1651-226X.2026.45677","DOIUrl":"10.2340/1651-226X.2026.45677","url":null,"abstract":"<p><strong>Background and purpose: </strong>This study evaluates volumetric modulated arc therapy (VMAT) as a potential alternative to three-dimensional conformal radiotherapy (3D-CRT) for whole-breast radiotherapy (RT) with simultaneous-integrated boost (SIB). Patient/material and methods: Ten left-sided breast cancer patients previously treated in our institution (whole breast with SIB) were selected. Clinical plans were generated using tangential field-in-field 3D-CRT technique. VMAT plans were retrospectively created. Dosimetric evaluation was performed according to our clinical guidelines. A robustness evaluation of the 3D-CRT and VMAT plans against simulated anatomical and setup uncertainties was also performed. Differences between techniques were analysed using a two-sided Wilcoxon signed-rank test with a significance level of 0.05.</p><p><strong>Results: </strong>Both the 3D-CRT and VMAT plans fulfilled the clinical requirements for target volumes and organs at risk. VMAT plans showed a median increase in heart mean dose of 10.8%, compared to 3D-CRT (p < 0.05). Heart maximum dose was reduced by up to 56.7% with VMAT (p < 0.05), offering a clinically meaningful advantage. For the ipsilateral lung, no significant difference in mean dose was observed, V16Gy was significantly lower and V4Gy was significantly increased with VMAT. VMAT plans improved dose conformity to the boost planning target volume, (p < 0.05). Median monitor units (MU) values of 371 MU (359-466 MU) vs 927 MU (752-1018 MU) were obtained with 3D-CRT and VMAT. VMAT remained robust to simulated uncertainties for whole-breast but showed greater sensitivity in the boost volume.</p><p><strong>Interpretation: </strong>VMAT was a feasible alternative to 3D-CRT for whole-breast RT with SIB, improving boost dose-conformity and reducing maximum heart dose. However, VMAT requires careful dosimetric evaluation and robustness assessment.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"543-552"},"PeriodicalIF":2.7,"publicationDate":"2026-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148269916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perspectives on artificial intelligence-generated chronic disease risk predictions in early breast cancer: an international survey among radiation oncologists.","authors":"Frederik Voigt Carstensen, Belinda Bøgh Irankunda, Eva Batista, Desiree Van den Bongard, Tanja Spanic, Sofie A M Gernaat, Helena Verkooijen, Maja Vestmø Maraldo","doi":"10.2340/1651-226X.2026.45901","DOIUrl":"10.2340/1651-226X.2026.45901","url":null,"abstract":"","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"553-556"},"PeriodicalIF":2.7,"publicationDate":"2026-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148269937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}